# STOPNET (NCT06345079)

> Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06345079
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Australasian Gastro-Intestinal Trials Group
- Conditions: Neuroendocrine Tumors
- Interventions: Cessation of somatostatin analogues; Continuation of somatostatin analogues
- Enrollment: 78
- Primary outcome: 20-month progression free survival rate after PRRT
- Primary outcome: Assess the barriers which would impede the feasibility of a subsequent phase 3 trial

## Commentary we found

- YouTube: 5
- X threads: 3
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=stopnet-nct06345079

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06345079", "email": "<work email>"}; the inbox owner confirms by the emailed link.